A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency.

Chen RG, Shen YN, Yei J, Wang CF, Xie DH, Wang XH, Zhou JD, Chen CY, Wu YL, Gunnarsson R

Acta paediatrica (Oslo, Norway : 1992). Supplement1 Mar 1993Cited by 4 (Europe PMC)

PMID8329830DOI10.1111/j.1651-2227.1993.tb12834.xPepBankPUB-08329830

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with hypothalamic GH deficiency, growth with 30 micrograms/kg/day GHRH(1-29)-NH2 was significantly worse than with GH.
In plain wordsIn children with growth hormone deficiency, 30 micrograms/kg/day GHRH(1-29)-NH2 gave less growth than growth hormone.
Peptide
Sermorelin
Outcome
DecreaseGrowth (height velocity) with 30 micrograms/kg/day GHRH versus GH
Study
n = 60
Comparator
GH 0.1 IU/kg/day
Outcome group
Linear growth · Endocrine and hormones
Studied dose
30 micrograms/kg/day · 6 monthsAs given in this study (human).
Measurements
Mean height velocity
9.2 cm/year
GHRH 30 micrograms/kg/day
Mean height velocity
14.6 cm/year
GH
Source sentences
Summary
There were no significant differences in growth between the two groups given GHRH(1-29)-NH2, but growth in the GH group was significantly better than in the other two groups (p < 0.01). Mean height velocities at 6 months were 9.2, 9.3 and 14.6 cm/year for the three groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983001
02HumanRandomized controlled trialEfficacy outcome
In children with hypothalamic GH deficiency, growth with 60 micrograms/kg/day GHRH(1-29)-NH2 was significantly worse than with GH.
In plain wordsIn children with growth hormone deficiency, 60 micrograms/kg/day GHRH(1-29)-NH2 gave less growth than growth hormone.
Peptide
Sermorelin
Outcome
DecreaseGrowth (height velocity) with 60 micrograms/kg/day GHRH versus GH
Study
n = 60
Comparator
GH 0.1 IU/kg/day
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 micrograms/kg/day · 6 monthsAs given in this study (human).
Measurements
Mean height velocity
9.3 cm/year
GHRH 60 micrograms/kg/day
Mean height velocity
14.6 cm/year
GH
Source sentences
Summary
There were no significant differences in growth between the two groups given GHRH(1-29)-NH2, but growth in the GH group was significantly better than in the other two groups (p < 0.01). Mean height velocities at 6 months were 9.2, 9.3 and 14.6 cm/year for the three groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983002
03HumanRandomized controlled trialEfficacy outcome
In children with hypothalamic GH deficiency, growth did not differ significantly between the 30 and 60 micrograms/kg/day GHRH(1-29)-NH2 groups.
In plain wordsIn children with growth hormone deficiency, the two GHRH(1-29)-NH2 doses gave similar growth.
Peptide
Sermorelin
Outcome
No significant changeGrowth with the two GHRH doses
Study
n = 40
Comparator
GHRH(1-29)-NH2 60 versus 30 micrograms/kg/day
Outcome group
Linear growth · Endocrine and hormones
Studied dose
30 and 60 micrograms/kg/day · 6 monthsAs given in this study (human).
Source sentences
Summary
There were no significant differences in growth between the two groups given GHRH(1-29)-NH2
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983003
04HumanRandomized controlled trialSafety outcome
In children with hypothalamic GH deficiency, all 20 patients on high-dose GHRH(1-29)-NH2 developed GHRH antibodies.
In plain wordsIn children with growth hormone deficiency, all 20 children on high-dose GHRH(1-29)-NH2 developed antibodies against GHRH.
Peptide
Sermorelin
Outcome
Not applicableGHRH antibodies on high-dose GHRH
Study
n = 20
Outcome group
Immune response · Immune and inflammation
Studied dose
60 micrograms/kg/day · 6 monthsAs given in this study (human).
Measurements
Patients developing GHRH antibodies
20 of 20 patients
high-dose GHRH
Source sentences
Summary
No GH antibodies were detected, but all 20 patients on high-dose GHRH(1-29)-NH2 and 19 of 20 patients on low-dose GHRH(1-29)-NH2 developed GHRH antibodies.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983007
05HumanRandomized controlled trialSafety outcome
In children with hypothalamic GH deficiency, 19 of 20 patients on low-dose GHRH(1-29)-NH2 developed GHRH antibodies.
In plain wordsIn children with growth hormone deficiency, 19 of 20 children on low-dose GHRH(1-29)-NH2 developed antibodies against GHRH.
Peptide
Sermorelin
Outcome
Not applicableGHRH antibodies on low-dose GHRH
Study
n = 20
Outcome group
Immune response · Immune and inflammation
Studied dose
30 micrograms/kg/day · 6 monthsAs given in this study (human).
Measurements
Patients developing GHRH antibodies
19 of 20 patients
low-dose GHRH
Source sentences
Summary
No GH antibodies were detected, but all 20 patients on high-dose GHRH(1-29)-NH2 and 19 of 20 patients on low-dose GHRH(1-29)-NH2 developed GHRH antibodies.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983008
06HumanRandomized controlled trialPharmacokinetics
In children with hypothalamic GH deficiency, plasma GHRH concentrations increased steadily over 6 months of treatment, with higher levels on the higher dose.
In plain wordsIn children with growth hormone deficiency, GHRH levels in the blood rose steadily during 6 months of treatment and were higher with the higher dose.
Peptide
Sermorelin
Outcome
IncreasePlasma GHRH concentration during treatment
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
30 and 60 micrograms/kg/day · 6 monthsAs given in this study (human).
Source sentences
Summary
Plasma GHRH concentrations increased steadily over the 6-month treatment period, with higher levels in the group on the higher dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983004
07HumanRandomized controlled trialActivity measurement
In children with hypothalamic GH deficiency, serum IGF-I rose initially during GHRH(1-29)-NH2 treatment, then fell to values similar to those before treatment.
In plain wordsIn children with growth hormone deficiency on GHRH(1-29)-NH2, IGF-I rose at first and then returned to the level before treatment.
Peptide
Sermorelin
Outcome
MixedSerum IGF-I during GHRH(1-29)-NH2 treatment
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 and 60 micrograms/kg/day · 6 monthsAs given in this study (human).
Source sentences
Summary
During GHRH(1-29)-NH2 treatment, serum concentrations of insulin-like growth factor I rose initially, but then fell to values similar to those before treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983005
08HumanRandomized controlled trialSafety outcome
In children with hypothalamic GH deficiency treated with GHRH(1-29)-NH2, no GH antibodies were detected.
In plain wordsIn children with growth hormone deficiency on GHRH(1-29)-NH2, no antibodies against growth hormone were found.
Peptide
Sermorelin
Outcome
No significant changeGH antibodies
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Studied dose
30 and 60 micrograms/kg/day · 6 monthsAs given in this study (human).
Source sentences
Summary
No GH antibodies were detected, but all 20 patients on high-dose GHRH(1-29)-NH2 and 19 of 20 patients on low-dose GHRH(1-29)-NH2 developed GHRH antibodies.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983006
09HumanRandomized controlled trialSafety outcome
In children with hypothalamic GH deficiency, GHRH antibodies had almost disappeared by 9 months after GHRH(1-29)-NH2 treatment stopped.
In plain wordsIn children with growth hormone deficiency, antibodies against GHRH had almost gone 9 months after stopping GHRH(1-29)-NH2.
Peptide
Sermorelin
Outcome
DecreaseGHRH antibodies after stopping treatment
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Studied dose
30 and 60 micrograms/kg/day · 6 monthsAs given in this study (human).
Source sentences
Summary
These had almost disappeared by 9 months after stopping treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983009
10HumanRandomized controlled trialEfficacy outcome
In children with hypothalamic GH deficiency, antibody titres did not correlate with the increase in height during GHRH(1-29)-NH2 treatment.
In plain wordsIn children with growth hormone deficiency, antibody levels were not linked to how much the children grew on GHRH(1-29)-NH2.
Peptide
Sermorelin
Outcome
No significant changeCorrelation between antibody titre and height increase
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
30 and 60 micrograms/kg/day · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no correlation between antibody titres and increase in height.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983010
11HumanRandomized controlled trialSafety outcome
In children with hypothalamic GH deficiency treated with GHRH(1-29)-NH2, no serious side-effects were seen.
In plain wordsIn children with growth hormone deficiency on GHRH(1-29)-NH2, no serious side-effects were seen.
Peptide
Sermorelin
Outcome
No significant changeSerious side-effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
30 and 60 micrograms/kg/day · 6 monthsAs given in this study (human).
Source sentences
Summary
No serious side-effects were seen, but three patients receiving GHRH(1-29)-NH2 reported mild irritation at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983011
12HumanRandomized controlled trialSafety outcome
In children with hypothalamic GH deficiency, three patients receiving GHRH(1-29)-NH2 reported mild irritation at the injection site.
In plain wordsIn children with growth hormone deficiency, three children on GHRH(1-29)-NH2 reported mild irritation where they were injected.
Peptide
Sermorelin
Outcome
Not applicableInjection-site irritation
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Studied dose
30 and 60 micrograms/kg/day · 6 monthsAs given in this study (human).
Source sentences
Summary
three patients receiving GHRH(1-29)-NH2 reported mild irritation at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months.
Report a problemFND-0832983012

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.